Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Alcentra Capital (ABDC) Share Price

News coverage about Alcentra Capital (NASDAQ:ABDC) has been trending somewhat positive on Monday, Accern Sentiment Analysis reports. Accern identifies positive and negative press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Alcentra Capital earned a media sentiment score of 0.06 on Accern’s scale. Accern also assigned media stories about the asset manager an impact score of 45.819912406352 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Shares of Alcentra Capital (ABDC) opened at $8.88 on Monday. The firm has a market capitalization of $126.50, a price-to-earnings ratio of -177.56 and a beta of 0.62. Alcentra Capital has a twelve month low of $7.00 and a twelve month high of $14.73.

Alcentra Capital (NASDAQ:ABDC) last announced its quarterly earnings data on Monday, November 6th. The asset manager reported $0.34 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.33 by $0.01. The business had revenue of $7.61 million during the quarter. Alcentra Capital had a positive return on equity of 11.32% and a negative net margin of 2.25%. research analysts forecast that Alcentra Capital will post 1.29 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Thursday, January 4th. Stockholders of record on Friday, December 29th were issued a $0.25 dividend. The ex-dividend date was Thursday, December 28th. This represents a $1.00 annualized dividend and a dividend yield of 11.26%. Alcentra Capital’s dividend payout ratio (DPR) is -1,999.60%.

Alcentra Capital announced that its Board of Directors has authorized a stock buyback plan on Monday, November 6th that permits the company to repurchase $2.50 million in shares. This repurchase authorization permits the asset manager to reacquire shares of its stock through open market purchases. Stock repurchase plans are usually an indication that the company’s leadership believes its stock is undervalued.

ABDC has been the subject of a number of analyst reports. Rowe lowered Alcentra Capital from an “outperform” rating to an “underperform” rating in a research report on Wednesday, November 8th. ValuEngine upgraded Alcentra Capital from a “hold” rating to a “buy” rating in a report on Monday, October 2nd. Raymond James Financial upgraded Alcentra Capital from an “underperform” rating to a “market perform” rating in a report on Thursday. UBS Group lowered Alcentra Capital from an “outperform” rating to an “underperform” rating in a report on Wednesday, November 8th. Finally, Keefe, Bruyette & Woods restated a “hold” rating and issued a $9.50 price objective on shares of Alcentra Capital in a report on Friday, November 10th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the company. Alcentra Capital presently has a consensus rating of “Hold” and an average price target of $12.83.

In related news, Director Steven H. Reiff bought 6,900 shares of the business’s stock in a transaction dated Monday, November 13th. The shares were bought at an average cost of $7.23 per share, with a total value of $49,887.00. Following the completion of the transaction, the director now directly owns 35,246 shares of the company’s stock, valued at $254,828.58. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Paul J. Echausse sold 10,000 shares of the business’s stock in a transaction on Thursday, November 9th. The stock was sold at an average price of $7.45, for a total value of $74,500.00. Following the sale, the director now directly owns 58,946 shares in the company, valued at $439,147.70. The disclosure for this sale can be found here. In the last 90 days, insiders bought 11,730 shares of company stock valued at $83,956. Insiders own 4.96% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this piece on another site, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece can be viewed at https://stocknewstimes.com/2018/01/15/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-alcentra-capital-abdc-share-price.html.

About Alcentra Capital

Alcentra Capital Corporation is a specialty finance company that operates as a non-diversified, closed-end management investment company. The Company operates as a business development company and a regulated investment company. It provides customized debt and equity financing solutions to lower middle-market companies, which are companies having annual earnings, before interest, taxes, depreciation and amortization of between $5 million and $15 million, and/or revenues of between $10 million and $100 million.

Insider Buying and Selling by Quarter for Alcentra Capital (NASDAQ:ABDC)

Receive News & Ratings for Alcentra Capital Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alcentra Capital and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply